1. Home
  2. TNET vs TRVI Comparison

TNET vs TRVI Comparison

Compare TNET & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$62.41

Market Cap

3.0B

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$13.27

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
TRVI
Founded
1988
2011
Country
United States
United States
Employees
2700
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
TNET
TRVI
Price
$62.41
$13.27
Analyst Decision
Hold
Strong Buy
Analyst Count
7
10
Target Price
★ $66.20
$28.18
AVG Volume (30 Days)
251.2K
★ 1.6M
Earning Date
10-28-2026
11-12-2026
Dividend Yield
★ 1.81%
N/A
EPS Growth
N/A
★ 31.91
EPS
★ 3.05
N/A
Revenue
★ $5,010,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.80
N/A
P/E Ratio
$20.97
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$33.67
$9.29
52 Week High
$73.08
$20.22

Technical Indicators

Market Signals
Indicator
TNET
TRVI
Relative Strength Index (RSI) 38.53 22.34
Support Level $59.61 $13.08
Resistance Level $64.37 $13.55
Average True Range (ATR) 1.87 0.56
MACD -0.44 -0.08
Stochastic Oscillator 8.54 10.70

Price Performance

Historical Comparison
TNET
TRVI

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: